<DOC>
	<DOCNO>NCT02824757</DOCNO>
	<brief_summary>This study aim explore effect glucocorticoid glucose metabolism patient interstitial lung disease . Patients interstitial lung disease medication 15mg prednisolone 7.5mg prednisolone conduct continuous glucose monitoring ( CGM ) . The data attain CGM use define glycemic characteristic patient use glucocorticoid difference glucose feature due different dos .</brief_summary>
	<brief_title>The Effects Glucocorticoids Glucose Metabolism Patients With Interstitial Lung Disease</brief_title>
	<detailed_description>Patients diagnose interstitial lung disease treat glucocorticoid could enrol clinical trial . Those acute inflammatory phase diagnose hemorrhagic disease exclude , unwilling carry continuous glucose monitoring ( CGM ) device . When dose prednisolone apply 15mg per day steadily go decrease , CGM conduct . At time , blood test evaluate glucose metabolism measure , include HbA1c , GA , fast insulin fast glucose . After take 7.5mg prednisolone per day 3 month , participant CGM blood test evaluate glucose metabolism period . The CGM data could use glucose evaluation , manifest glucose characteristic circumstance glucocorticoid use . By compare CGM data blood test , investigator hope find different feature glucose metabolism due different dos .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Patients diagnose interstitial lung disease Patients acute inflammatory phase Patients diagnose hemorrhagic disease Patients unwilling carry continuous glucose monitoring device</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>interstitial lung disease</keyword>
	<keyword>glucocorticcoid</keyword>
	<keyword>glucose</keyword>
	<keyword>continuous glucose monitor</keyword>
</DOC>